CD8A and breast cancer: Similar results were obtained when NKp30 CAR engineered T lymphocytes derived from BC 2 with higher numbers of CD8+ T cells were examined for B7H6-mediated cytolytic activity, suggesting that NKp30-CD28 CAR T effectors were more effective in vitro (Figure 5B).